Peter Meldgaard

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5166414/publications.pdf

Version: 2024-02-01

		331259	168136
63	2,928	21	53
papers	citations	h-index	g-index

63	63	63	5083
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Annals of Oncology, 2014, 25, 1462-1474.	0.6	410
2	2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Annals of Oncology, 2015, 26, 1573-1588.	0.6	308
3	Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Annals of Oncology, 2014, 25, 1681-1690.	0.6	246
4	Exosomal Proteins as Diagnostic Biomarkers inÂLungÂCancer. Journal of Thoracic Oncology, 2016, 11, 1701-1710.	0.5	213
5	2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Annals of Oncology, 2014, 25, 1475-1484.	0.6	210
6	Monitoring of epidermal growth factor receptor tyrosine kinase inhibitorâ€sensitizing and resistance mutations in the plasma DNA of patients with advanced nonâ€“small cell lung cancer during treatment with erlotinib. Cancer, 2014, 120, 3896-3901.	2.0	180
7	Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays. BMC Cancer, 2014, 14, 294.	1.1	135
8	Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation in the Epidermal Growth Factor Receptor. Journal of Thoracic Oncology, 2011, 6, 1287-1289.	0.5	124
9	Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR -mutated non-small cell lung cancer treated with erlotinib. Lung Cancer, 2016, 100, 77-84.	0.9	97
10	PD-L1 Expression and Survival among Patients with Advanced Nonâ€“Small Cell Lung Cancer Treated with Chemotherapy. Translational Oncology, 2016, 9, 64-69.	1.7	77
11	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. Journal of Thoracic Oncology, 2018, 13, 413-425.	0.5	66
12	Long-term bladder, colorectal, and sexual functions after radical radiotherapy for urinary bladder cancer. Radiotherapy and Oncology, 2004, 72, 139-145.	0.3	63
13	Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients. British Journal of Cancer, 2017, 117, 704-709.	2.9	45
14	EGFR mutation frequency and effectiveness of erlotinib: A prospective observational study in Danish patients with non-small cell lung cancer. Lung Cancer, 2014, 83, 224-230.	0.9	41
15	Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus. Lung Cancer, 2015, 87, 89-95.	0.9	40
16	A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. Lung Cancer, 2019, 131, 95-103.	0.9	40
17	Programmed Death Ligand 1 Expression in Paired Nonâ€“Small Cell Lung Cancer Tumor Samples. Clinical Lung Cancer, 2017, 18, e473-e479.	1.1	35
18	Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib. Lung Cancer, 2016, 94, 81-87.	0.9	34

#	Article	IF	Citations
19	Lungscape: Resected Nonâ€“Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters. Journal of Thoracic Oncology, 2014, 9, 1675-1684.	0.5	31
20	Frailty status but not age predicts complications in elderly cancer patients: a follow-up study. Acta OncolÃ³gica, 2018, 57, 1458-1466.	0.8	27
21	Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer. Lung Cancer, 2020, 141, 37-43.	0.9	24
22	Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients. Lung Cancer, 2019, 135, 92-96.	0.9	22
23	Comorbidity in Lung Cancer: A Prospective Cohort Study of Self-Reported versus Register-Based Comorbidity. Journal of Thoracic Oncology, 2018, 13, 54-62.	0.5	21
24	Up-Regulated FGFR1 Expression as a Mediator of Intrinsic TKI Resistance in EGFR-Mutated NSCLC. Translational Oncology, 2019, 12, 432-440.	1.7	20
25	Neurofilament Light Chain as A Biomarker for Brain Metastases. Cancers, 2020, 12, 2852.	1.7	20
26	Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients. Cancers, 2020, 12, 947.	1.7	20
27	Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLCâ€”Real World Efficacy. Cancers, 2021, 13, 4846.	1.7	19
28	The effect of direct access to CT scan in early lung cancer detection: an unblinded, cluster-randomised trial. BMC Cancer, 2015, 15, 934.	1.1	18
29	A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations. Oncotarget, 2018, 9, 31066-31076.	0.8	18
30	cGAS-STING pathway expression as a prognostic tool in NSCLC. Translational Lung Cancer Research, 2021, 10, 340-354.	1.3	18
31	Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Nonâ€“Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified byÂVeriStrat Good versus VeriStrat Poor. The EuropeanÂThoracic Oncology Platform (ETOP) EMPHASIS-lung Trial. Journal of Thoracic Oncology, 2017, 12, 752-762.	0.5	17
32	Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients. Lung Cancer, 2020, 143, 67-72.	0.9	17
33	¹⁸F-FDG PET/CT for Very Early Response Evaluation Predicts CT Response in Erlotinib-Treated Nonâ€“Small Cell Lung Cancer Patients: A Comparison of Assessment Methods. Journal of Nuclear Medicine, 2017, 58, 1931-1937.	2.8	16
34	Impact of comprehensive geriatric assessment on short-term mortality in older patients with cancerâ€”a follow-up study. European Journal of Cancer, 2019, 116, 27-34.	1.3	15
35	The prognostic role of inflammation-scores on overall survival in lung cancer patients. Acta OncolÃ³gica, 2019, 58, 371-376.	0.8	15
36	The impact of a tailored follow-up intervention on comprehensive geriatric assessment in older patients with cancer - a randomised controlled trial. Journal of Geriatric Oncology, 2021, 12, 41-48.	0.5	15

#	Article	IF	Citations
37	The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment. BMC Cancer, 2018, 18, 191.	1.1	14
38	Intraâ€individual variation of circulating tumour DNA in lung cancer patients. Molecular Oncology, 2019, 13, 2098-2106.	2.1	14
39	Surgery for NSCLC stages T1-3N2M0 having preoperative pathologically verified N2 involvement: A prospective randomized multinational phase III trial by the Nordic Thoracic Oncology Group.. Journal of Clinical Oncology, 2013, 31, 7504-7504.	0.8	14
40	Intravenous or oral administration of vinorelbine in adjuvant chemotherapy with cisplatin and vinorelbine for resected NSCLC. Lung Cancer, 2015, 88, 167-173.	0.9	13
41	Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib. Lung Cancer, 2015, 90, 314-320.	0.9	13
42	Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients. Translational Oncology, 2016, 9, 505-511.	1.7	13
43	EGFR Gene Polymorphism Predicts Improved Outcome in Patients With EGFR Mutation-positive Nonâ€“small cell Lung Cancer Treated With Erlotinib. Clinical Lung Cancer, 2019, 20, 161-166.e1.	1.1	13
44	Complete Pathologic Response in Lung Tumors in Two Patients with Metastatic Non-small Cell Lung Cancer Treated with Erlotinib. Journal of Thoracic Oncology, 2011, 6, 1946-1949.	0.5	12
45	Dasatinib and Doxorubicin Treatment of Sarcoma Initiating Cells: A Possible New Treatment Strategy. Stem Cells International, 2016, 2016, 1-8.	1.2	12
46	Cell-free Chromatin Immunoprecipitation (cfChIP) from blood plasma can determine gene-expression in tumors from non-small-cell lung cancer patients. Lung Cancer, 2020, 147, 244-251.	0.9	12
47	Loss of abh antigen expression in bladder cancer is not caused by loss of heterozygosity of the ABO locus. International Journal of Cancer, 1995, 63, 341-344.	2.3	11
48	EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib. Lung Cancer, 2014, 85, 435-441.	0.9	11
49	Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study. Acta OncolÃ³gica, 2022, 61, 409-416.	0.8	11
50	Characterization of pulmonary lesions in patients with suspected lung cancer: computed tomography versus [18F]fluorodeoxyglucose-positron emission tomography/ computed tomography. Cancer Imaging, 2012, 12, 437-446.	1.2	8
51	Gene Expression of the EGF Systemâ€”a Prognostic Model in Nonâ€“Small Cell Lung Cancer Patients Without Activating EGFR Mutations. Translational Oncology, 2016, 9, 306-312.	1.7	7
52	Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy: A Randomized Controlled Trial (SUPER). Clinical Lung Cancer, 2020, 21, e61-e64.	1.1	7
53	EGFR transcription in nonâ€smallâ€cell lung cancer tumours can be revealed in ctDNA by cellâ€free chromatin immunoprecipitation (cfChIP). Molecular Oncology, 2021, 15, 2868-2876.	2.1	7
54	Co-occurring MET Amplification Predicts Inferior Clinical Response to First-Line Erlotinib in Advanced Stage EGFR-Mutated NSCLC Patients. Clinical Lung Cancer, 2021, 22, e870-e877.	1.1	6

#	Article	IF	Citations
55	Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC. Case Reports in Oncology, 2022, 14, 1323-1327.	0.3	4
56	A new quantitative RTâ€“PCR assay for thymidylate synthase mRNA in blood leukocytes applied to cancer patients and healthy controls. Clinica Chimica Acta, 2000, 290, 129-144.	0.5	3
57	Ultra-micro samples can be used for mRNA quantification of lung cancer biomarkers. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, 243-248.	0.6	2
58	The European Thoracic Oncology Platform Lungscape project: Clinical outcome data as a basis for molecular correlations in resected non-small cell lung cancer.. Journal of Clinical Oncology, 2013, 31, 7514-7514.	0.8	2
59	TDP1 and TOP1 as targets in anticancer treatment of NSCLC: Activity and protein level in normal and tumor tissue from 150 NSCLC patients correlated to clinical data. Lung Cancer, 2022, 164, 23-32.	0.9	2
60	Protein expression of programmed cell death ligand 1 and ligand 2 and their prognostic values in extensive-stage small cell lung cancer.. Journal of Clinical Oncology, 2021, 39, e20593-e20593.	0.8	0
61	Metronomic oral vinorelbine doublet chemotherapy with carboplatin in treatment of advanced lung cancer: a feasibility and safety study. F1000Research, 0, 10, 673.	0.8	0
62	Intravenous or oral administration of vinorelbine in adjuvant chemotherapy with cisplatin and vinorelbine after surgery for NSCLC.. Journal of Clinical Oncology, 2014, 32, e18501-e18501.	0.8	0
63	Randomized phase III trial of erlotinib vs. docetaxel in patients with advanced squamous cell non-small cell lung cancer (SqNSCLC) failing first line platinum based doublet chemotherapy stratified by VeriStrat Good vs VeriStrat Poor: The European Thoracic Oncology Platform (ETOP) EMPHASIS trial.. Journal of Clinical Oncology, 2015, 33, 8049-8049.	0.8	0